Netherlands compounding pharmacies market | Coherent Market Insights

1. Coherent Marketing Insights https://www.coherentmarketinsights.com/ Market Research & Business Consulting Services Covid-19 Impact Tracker

2. NETHERLANDS COMPOUNDING PHARMACIES MARKET ANALYSIS Netherlands Compounding Pharmacies Market, By Product Type (Mouthwashes, Oral Medication (Capsule, Lollipops, Lozenges, Suspensions,Tablets), Suppositories Topical Medication (Cream, Gels, Lotions, Ointments)), By Application (Medication for Adults, Medication for Children, Medication for Geriatric, Medication for Veterinary), By Therapeutic Area (Hormone Replacement Therapy, Pain Management), By Facilities (Community Pharmacies, Hospitals) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

3. Netherlands Compounding Pharmacies Market: Drivers Increasing prevalence of chronic diseases is expected to boost growth of the Netherlands compounding pharmacies market over the forecast period. For instance, according to Globocan 2018, 119,923 cases of cancer were registered in the Netherlands. Moreover, decreasing supply of essential drugs is also expected to propel growth of the market. For instance, according to Royal Dutch Society for the Promotion of Pharmacy (KNMP), 769 medicines were unavailable at some stage during 2018, including 128 treatments that were taken out of circulation altogether. Oral medication held dominant position in the Netherlands compounding pharmacies market in 2018, accounting for 62.9% share in terms of value, followed by topical medication.

5. Netherlands Compounding Pharmacies Market: Restraints However, a major factor hindering growth of the Netherlands compounding pharmacies market is adoption of unsafe compounding practices such as compounding contamination and non-adherence to GMP regulations. Moreover, certain compounded drugs in the Netherlands have been associated with adverse drug reactions as they constitute drugs that are banned under pharmacovigilance measures. Adverse drug reactions prove detrimental to patient’s and related party’s confidence in compounded drugs. For instance, clioquinol—a drug used for controlling amoebiasis and infections with dientamoeba fragilis—is no longer registered through the Medicines Evaluation Board for systemic use in the Netherlands and is only available as a compounded drug. In 2015, according to Netherlands Pharmacovigilance Center, use of clioquinol in compounded form led to 33 reports concerning adverse drug reactions.

6. Netherlands Compounding Pharmacies Market: Opportunities Increasing GMP compliance is expected to offer lucrative growth opportunities for players in the Netherlands compounding pharmacies market. Currently, inspection for adherence to GMP guidelines is only available for industrial manufacturing of drugs in the Netherlands. However, community compounding pharmacies need to adhere to best practice guidelines, as hospitals in the country are expected to outsource more drug compounding to the community compounding pharmacies. Key players in the market can also focus on R&D of products related to geriatric and long-term care and innovative Hormone replacement therapy (HRT) applications to expand their product portfolio.

7. Market Trends/Key Takeaways The market is witnessing increasing preference for HRT drugs for indications such as menopausal symptoms, men’s health (andropause), and weight loss. However, untested ingredients, possibility of microbiological contaminations, errors in defining dosages of hormones and declining reimbursements from government are some of the factors that may hamper demand for HRT drugs in the Netherlands. In the Netherlands, products are primarily purchased from specialized compounding companies and products from major market players are in high demand compared to those of community compounding pharmacies. Moreover, a majority of compounded drugs are outsourced to hospitals.

8. Netherlands Compounding Pharmacies Market: Key Developments Key players in the market are focused on geographical expansion through M&A activities. For instance, in May 2019, Fagron entered into an agreement to acquire Central de Drogas, S.A. de C.V., a leading supplier of raw materials to compounding pharmacies and the pharmaceutical industry in Mexico. Key players in the market are also focused on product development to expand their product portfolio. For instance, in November 2018, AMC, a hospital in Amsterdam focused on producing compounding drugs, received permission from the Dutch Health and Youth Care Inspectorate to produce an equivalent of chenodeoxycholic acid (CDCA) if the used resources meet the quality standards.

9. Request Sample Report Request Customization Download PDF Brochure Talk to Analyst Referance: https://www.coherentmarketinsights.com/market-insight/netherlands-compounding-pharmacies-market-3156

10. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. What We Provide:Customized Market Research AnalysisIndustry Analysis ServicesBusiness Consulting ServicesLong Term Engagement ModelCountry Specific Analysis

11. Contact Us Mr. Shah Coherent Market Insights Pvt. LTD.Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S.Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

12. Thank You Kindly Follow CMI Social Media Profiles for the latest Company Updates. Facebook Linkedin Twitter https://www.coherentmarketinsights.com/